299 related articles for article (PubMed ID: 37916308)
61. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
62. Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S; Labadie BW; Argulian A; Patnaik A
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33572196
[TBL] [Abstract][Full Text] [Related]
63. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
[TBL] [Abstract][Full Text] [Related]
64. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
65. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.
Vasaturo A; Di Blasio S; Peeters DG; de Koning CC; de Vries JM; Figdor CG; Hato SV
Front Immunol; 2013 Dec; 4():417. PubMed ID: 24348481
[TBL] [Abstract][Full Text] [Related]
66. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells.
Munari E; Quatrini L; Ciancaglini C; Eccher A; Bogina G; Moretta L; Mariotti FR
Semin Immunol; 2022 Nov; 61-64():101660. PubMed ID: 36370672
[TBL] [Abstract][Full Text] [Related]
67. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
68. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
69. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
70. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.
Brown M
Cancer Treat Res; 2022; 183():91-129. PubMed ID: 35551657
[TBL] [Abstract][Full Text] [Related]
71. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
[TBL] [Abstract][Full Text] [Related]
72. Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Biochem Pharmacol; 2024 Feb; 220():116006. PubMed ID: 38142838
[TBL] [Abstract][Full Text] [Related]
73. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
74. The Impact of High Intensity Focused Ultrasound (HIFU) on Tumor-Specific Immune Responses of Prostate Cancer.
Chen W; He L; Huang H; Zeng X; Fu G; Liu Y; Liang Y
Arch Esp Urol; 2024 May; 77(4):322-330. PubMed ID: 38840273
[TBL] [Abstract][Full Text] [Related]
75. Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy.
Wei Q; Zhang L; Zhao N; Cheng Z; Xin H; Ding J
Front Immunol; 2022; 13():1012927. PubMed ID: 36389700
[TBL] [Abstract][Full Text] [Related]
76. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
77. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
78. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
79. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
80. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
